步行訓練器材市場：依產品類型、技術、輔助等級、應用和最終用戶分類－2026-2032年全球預測

2025 年步態訓練設備市場價值為 5.208 億美元，預計到 2026 年將成長至 5.6001 億美元，複合年成長率為 7.08%，到 2032 年將達到 8.409 億美元。

主要市場統計數據
基準年 2025	5.208億美元
預計年份：2026年	560,010,000 美元
預測年份 2032	8.409億美元
複合年成長率 (%)	7.08%

一個具有前瞻性的、情境化的框架，透過將步態訓練設備定位在不斷發展的臨床工作流程、技術能力和營運重點中，來指導策略決策。

隨著臨床醫生、醫療保健提供者和技術開發人員逐漸認知到步態訓練設備是衡量功能性活動能力的可測量臨床終點，步態訓練設備在現代復健實踐中扮演著日益重要的角色。近年來，機械創新、基於感測器的回饋和軟體驅動的個人化功能相融合，重新定義了復健團隊對步態訓練設備的期望。醫療機構在權衡臨床療效與人員配備、治療效率和報銷途徑等運作限制的同時，步態訓練設備不再僅僅被視為設備本身，而是被視為涵蓋康復前、住院治療和長期社區融入的更廣泛護理路徑中的關鍵環節。因此，相關人員需要一個框架，清晰地闡述產品設計、臨床證據和服務模式如何相互作用並影響其應用。

重組步態訓練的匯聚力量包括引入機器人、轉向以結果為導向的報銷制度、數據驅動的個人化以及確定促進供應彈性的因素。

步態訓練設備領域正經歷著一場變革，其驅動力來自多面向因素的交匯，包括機器人輔助技術的成熟、以結果為導向的臨床通訊協定的廣泛應用，以及能夠實現個人化治療方案的數據分析技術的進步。機器人系統已超越概念驗證階段，正逐步發展成為將外骨骼結構和末端執行器設計與自適應控制演算法結合的解決方案。同時，在成本敏感、易於維護和易用性至關重要的領域，非機器人機械設備仍然發揮著重要作用，從而建構了一個多層次的技術生態系統。

本研究評估了不斷變化的關稅壓力如何推動供應鏈重組、近岸外包選擇和籌資策略，從而影響設備可用性和總擁有成本。

近期影響進口零件和成品設備的關稅趨勢，為在美國採購環境中營運的製造商和機構買家帶來了更大的複雜性。關稅措施提高了設備和組件的到岸成本，促使企業重新評估籌資策略、庫存計劃和製造地。為此，醫療設備製造商正在評估近岸外包和多源採購策略，以減少對單一貿易路線的依賴，同時保持設計品質並符合法規要求。雖然這些轉型通常需要前期對供應商審核、工具複製和物流重新設計前期投資，但它們也為縮短前置作業時間和提高對臨床需求的應對力創造了機會。

該框架闡明了一個多維細分框架，涵蓋產品形式、技術架構、臨床適應症、醫療保健環境和支援強度，並將其作為優先排序的指南。

細緻的細分觀點揭示了產品開發、臨床檢驗和商業性合作的可行路徑。產品差異化體現在固定式系統、移動式系統、地面設備和跑步機平台等方面，每種系統都針對不同的治療方法和適用場所。固定式和跑步機系統通常用於高通量復健項目，而移動式和地面設備則適用於社區和居家復健。技術模式進一步分為非機器人技術和機器人技術。非機器人技術（包括手動和機械式）優先考慮簡單性、經濟性和易於維護性，通常用於早期移動訓練和資源有限的環境。機器人技術架構分為控制遠端肢體運動的末端執行器機制和提供節段支撐和協調關節輔助的外骨骼平台，每種架構在臨床和操作方面各有優劣。

透過分析區域需求因素，並轉向美洲、歐洲、中東和非洲以及亞太地區更受青睞的市場策略，我們將調整我們的產品和商業模式。

區域趨勢影響著步態訓練技術的應用、報銷系統以及與醫療服務路徑的整合，因此需要針對每個市場叢集制定相應的策略。在美洲，先進的復健網路、私人診所和大型醫療保健系統共同構成了對高性能機器人平台和經濟高效的非機器人解決方案的需求，這些解決方案可用於門診和居家復健計畫。區域監管環境和報銷機制往往重視功能改善的證據，這促使製造商投資於臨床試驗和真實世界數據收集，以支持採購談判。

透過分析策略供應商類型、合作趨勢和創新路徑，確定步態訓練設備生態系統中的競爭優勢。

競爭格局呈現出多元化的特點，既有成熟的醫療設備製造商，也有專業機器人公司、新興Start-Ups以及來自其他領域的技術參與企業。成熟的製造商利用其成熟的監管合規經驗、配銷通路和服務網路來擴大設備部署；而專業機器人公司則致力於開發核心控制系統、感測器融合技術和自適應演算法，以實現更個人化的治療。Start-Ups新創公司通常專注於特定的臨床應用領域、精簡的製造方法或以軟體主導的經營模式，將硬體與附加價值服務分開。

領導者應專注於以下策略事項：加速臨床部署、增強供應韌性、在醫療保健領域推廣永續的商業模式。

產業領導者可以透過採取一系列切實可行的優先步驟，將洞察轉化為競爭優勢，這些步驟涵蓋技術、證據、供應鏈韌性和商業性可行性。首先，調整研發藍圖，優先考慮模組化和跨架構相容性，可縮短產品上市時間，並為現有客戶提供維修路徑。其次，透過早期投資臨床通訊協定並與復健網路合作，產生真實世界證據，可以增強對支付方的價值提案，並加速產品在醫療機構中的應用。第三，將區域製造地與檢驗的二級供應商結合的供應鏈策略，可以提高服務反應速度，同時降低關稅風險。

為了確保證據的可靠性，我們採用了穩健的混合研究通訊協定，該方案結合了相關人員訪談、臨床觀察、監管審查和三角驗證的二級資訊來源。

本分析採用混合方法設計，將與關鍵相關人員的直接對話與全面的二手調查分析相結合，以確保研究的嚴謹性和相關性。主要調查包括對臨床醫生、採購專員、復健中心主任和醫療設備技術人員進行半結構式訪談，以收集他們對設備性能、工作流程整合和採購標準的直接意見。為補充訪談內容，臨床現場考察和觀察評估提供了有關治療工作流程、患者處理能力和培訓需求的背景資訊。原始資料經過匿名化和檢驗，以保護隱私，同時能夠發現不同環境下的模式。

綜合分析結論，將技術選擇、臨床證據優先排序和供應彈性聯繫起來，以指導可操作的策略，從而加速採用並實現價值。

透過整合技術趨勢、市場細分資訊、關稅影響和區域趨勢，我們為經營團隊、臨床醫生和投資者得出了全面的結論。首先，市場不再是機器人與非機器人之間的二元選擇，而是連續體，架構選擇取決於臨床目標、醫療環境限制和成本考量。其次，臨床檢驗和真實世界證據對於採購和報銷至關重要，因此，早期投資於研究設計和夥伴關係是一項策略挑戰。第三，透過供應商多元化、模組化設計和區域組裝實現的供應鏈敏捷性正在成為一項核心韌性能力，對產品可用性和總成本結果產生重大影響。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 市場進入策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：步行訓練器材市場：依產品類型分類

• 固定的
• 移動的
• 地面類型
• 跑步機底座

第9章：步行訓練設備市場：依技術分類

• 非機器人類型
  • 手動輸入
  • 機械的
• 機器人
  • 末端執行器
  • 外骨骼底座

第10章：步行訓練設備的市場支援水平

• 全身重量支撐
• 部分重量支撐
• 獨立步行訓練

第11章：步行訓練器材市場：依應用領域分類

• 神經復健
  • 帕金森氏症
  • 脊髓損傷
  • 中風
• 整形外科復健
  • 骨折恢復
  • 術後
• 運動復健

第12章：步行訓練設備市場：依最終用戶分類

• 門診部
• 居家醫療環境
• 醫院
• 復健中心

第13章：步行訓練器材市場：依地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章：步行訓練設備市場：依類別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章：步行訓練設備市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章：美國步行訓練設備市場

第17章：中國步行訓練器市場

第18章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• AlterG, Inc.
• Bionik Laboratories Corp.
• Cyberdyne Inc.
• Ekso Bionics, Inc.
• Hocoma AG
• Ottobock SE & Co. KGaA
• P&S Mechanics Co., Ltd.
• Parker-Hannifin Corporation
• ReWalk Robotics Ltd.
• Rex Bionics Ltd.
• Tyromotion GmbH

The Gait Trainer Market was valued at USD 520.80 million in 2025 and is projected to grow to USD 560.01 million in 2026, with a CAGR of 7.08%, reaching USD 840.90 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 520.80 million
Estimated Year [2026]	USD 560.01 million
Forecast Year [2032]	USD 840.90 million
CAGR (%)	7.08%

A forward-looking contextual framework that situates gait trainers within evolving clinical workflows, technology capabilities, and operational priorities to guide strategic decisions

Gait trainers occupy an increasingly central role in contemporary rehabilitation practice as clinicians, providers, and technology developers converge on functional mobility as a measurable clinical endpoint. Over recent years, the convergence of mechanical innovation, sensor-enabled feedback, and software-driven personalization has redefined what rehabilitation teams expect from assistive gait devices. As institutions seek to balance clinical efficacy with operational constraints such as staffing, throughput, and reimbursement pathways, gait trainers are evaluated not only as devices but as nodes within broader care pathways that include prehabilitation, inpatient therapy, and long-term community reintegration. Consequently, stakeholders require a clear framework that articulates how product design, clinical evidence, and service models interact to influence adoption.

From the perspective of clinicians and program managers, gait trainers must demonstrate reproducible patient outcomes, streamlined integration into therapy workflows, and compatibility with existing physical and electronic infrastructure. From the perspective of procurement and supply chain teams, considerations center on maintainability, interoperability, and total cost of ownership. For developers and investors, the primary questions concern scalability of technology platforms and the ability to translate lab-stage innovations into regulated, reimbursable solutions. This introduction frames the balance of clinical promise and pragmatic constraints, setting the stage for a focused examination of technological shifts, segmentation intelligence, regional dynamics, and practical recommendations to guide strategic decision making across the ecosystem.

Identifying convergent forces reshaping gait training including robotics adoption, outcome-driven reimbursement shifts, data-enabled personalization, and supply resilience drivers

The landscape for gait trainers is undergoing transformative shifts driven by multiple converging forces, including the maturation of robotic assistance, the proliferation of outcome-driven clinical protocols, and the maturation of data analytics that enable individualized therapy trajectories. Robotic systems are moving beyond proof-of-concept demonstrations toward integrated solutions that combine exoskeleton architectures and end-effector designs with adaptive control algorithms. At the same time, non-robotic mechanical devices remain relevant where cost sensitivity, simple maintenance, and ease of use are paramount, ensuring a multi-tiered technology ecosystem.

Concurrently, payor and regulatory environments are evolving to reward documented functional gains and reduced downstream care utilization, which incentivizes robust clinical validation and real-world evidence collection. Health systems are also reconfiguring care delivery to extend rehabilitation beyond inpatient settings, creating demand for devices that support ambulatory care and home-based programs while preserving clinician oversight through telemonitoring and remote analytics. Supply chain resilience has gained prominence, prompting manufacturers to diversify component sourcing and adopt modular designs to mitigate geopolitical and tariff-driven disruptions. Collectively, these shifts favor products and business models that blend clinical efficacy, data interoperability, and operational flexibility, thereby enabling sustainable adoption across diverse care settings.

Evaluating how evolving tariff pressures are prompting supply chain realignment, nearshoring choices, and procurement strategies that affect device availability and total cost of ownership

Recent tariff dynamics affecting imported components and finished devices have introduced an additional layer of complexity for manufacturers and institutional buyers operating within the United States procurement environment. Tariff measures can increase landed costs for devices and subassemblies, prompting firms to reassess their sourcing strategies, inventory planning, and manufacturing footprints. In response, device makers are evaluating nearshoring and multi-sourcing approaches that reduce exposure to a single trade corridor while preserving engineering quality and compliance with regulatory requirements. These shifts often require upfront investment in supplier audits, tooling duplication, and logistics redesign, but they also create opportunities to shorten lead times and enhance responsiveness to clinical demand.

For health systems and purchasing groups, tariff-related cost pressures necessitate a more nuanced procurement calculus that weighs immediate price implications against longer-term benefits such as reduced downtime, local serviceability, and warranty support. Consequently, commercial discussions increasingly emphasize total cost of ownership, service-level agreements, and bundled procurement options that include training and maintenance. Simultaneously, manufacturers with diversified supply networks are better positioned to sustain product availability during periods of trade friction, which in turn preserves clinical continuity. Ultimately, tariff considerations have catalyzed strategic reorientation across the value chain, elevating supply chain agility and localization as competitive differentiators.

Unpacking a multi-dimensional segmentation framework across product form factors, technology architectures, clinical indications, care settings, and assistance intensity to guide prioritization

A granular segmentation lens reveals actionable pathways for product development, clinical validation, and commercial engagement. Product differentiation spans fixed installations, mobile systems, overground devices, and treadmill-based platforms, each addressing distinct therapy modalities and facility footprints; fixed and treadmill-based systems typically serve high-throughput institutional programs, while mobile and overground solutions enable community and home-based rehabilitation trajectories. Technology modalities further bifurcate into non-robotic and robotic approaches. Within non-robotic solutions, manual and mechanical variants prioritize simplicity, affordability, and ease of maintenance, often serving early-stage mobility training or resource-constrained settings. Robotic architectures split between end effector mechanisms that control distal limb movement and exoskeleton platforms that provide segmental support and coordinated joint assistance, with each architecture offering distinct clinical and operational trade-offs.

Clinical application priorities direct product requirements toward neurological rehabilitation, orthopedic rehabilitation, and sports rehabilitation. Neurological pathways emphasize interventions for Parkinson's disease, spinal cord injury, and stroke and thus require high-fidelity feedback, gait symmetry metrics, and adaptive assistance levels. Orthopedic use cases focus on fracture recovery and post-surgery rehabilitation where controlled loading, progressions, and safety features are critical. Sports rehabilitation demands devices that support rapid progressions, agility training, and sport-specific movement retraining. End users range from ambulatory care facilities and homecare settings to hospitals and specialized rehabilitation centers, defining differences in staffing models, device utilization patterns, and support needs. Assistance level also structures design choices, spanning full body weight support to partial support and unassisted training, and these gradients determine sensor fidelity, control algorithms, and safety systems. Together, these segmentation axes inform differentiated value propositions, clinical evidence strategies, and go-to-market sequencing.

Translating regional demand drivers into prioritized market approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific to align product and commercial models

Regional dynamics shape how gait trainer technologies are adopted, reimbursed, and integrated into care pathways, requiring tailored strategies for each market cluster. In the Americas, a mixture of advanced rehabilitation networks, private clinics, and large health systems creates demand for both high-end robotic platforms and cost-effective non-robotic solutions that can be deployed across outpatient and home-based programs. The regulatory and reimbursement landscape in this region often rewards documented functional improvements, which incentivizes manufacturers to invest in clinical trials and real-world evidence collection to support procurement discussions.

Europe, Middle East & Africa presents heterogenous adoption landscapes driven by disparate regulatory frameworks, variable public funding mechanisms, and differing clinical practice models. In parts of Europe, consolidated purchasing and centralized evaluation processes favor devices with strong clinical evidence and lifecycle support. Middle Eastern markets often prioritize rapid implementation and partnership models, while certain African health systems focus on cost-effectiveness and maintainability. Asia-Pacific combines sophisticated pockets of innovation with large-scale volume markets; advanced economies in the region are early adopters of robotic systems and digital integration, whereas emerging markets prioritize affordability and serviceability. Across regions, successful market entry depends on aligning product design, distribution models, and clinical evidence strategies with local procurement realities and rehabilitation workforce configurations.

Profiling strategic vendor archetypes, collaboration trends, and innovation pathways that define competitive advantage in the gait trainer ecosystem

The competitive landscape is characterized by a blend of established medical device manufacturers, specialized robotics firms, emerging startups, and cross-sector technology entrants. Mature manufacturers leverage established regulatory expertise, distribution channels, and service networks to scale device deployment, while specialized robotics firms advance core control systems, sensor fusion, and adaptive algorithms that enable more personalized therapy. Emerging startups frequently focus on niche clinical applications, streamlined manufacturing approaches, or software-enabled business models that decouple hardware from value-added services.

Strategically significant patterns include an uptick in collaborative alliances between device makers and rehabilitation centers to co-develop clinical protocols, the proliferation of software-as-a-service offerings that monetize analytics and remote monitoring, and venture-backed innovation that accelerates proof-of-concept pipelines. Partnerships with academic centers and clinical networks remain vital for building robust evidence bases, enabling devices to transition from investigational use to clinical standard. Additionally, companies that invest in modular platforms and developer ecosystems can amplify third-party integrations, creating stickier solutions in institutional settings. For buyers, the choice matrix therefore includes not only technical performance but also the vendor's ecosystem, aftermarket support, and ability to demonstrate measurable clinical impact within local care models.

Actionable strategic priorities for leaders to accelerate clinical adoption, strengthen supply resilience, and scale sustainable commercial models across care settings

Industry leaders can convert insight into advantage by adopting a set of pragmatic, prioritized actions that address technology, evidence, supply resilience, and commercial execution. First, aligning R&D roadmaps to prioritize modularity and cross-architecture compatibility reduces time-to-market and supports retrofit pathways for existing customers. Second, investing early in clinical protocols and generating real-world evidence in partnership with rehabilitation networks strengthens payor value propositions and expedites institutional adoption. Third, supply chain strategies that combine regional manufacturing nodes with validated secondary suppliers mitigate tariff exposure while improving service response times.

From a commercial perspective, firms should design flexible pricing constructs that reflect different end-user realities, offering bundled solutions for hospitals and lighter-weight models or subscription services for ambulatory and homecare settings. Operationally, enhancing training programs, remote support capabilities, and digital onboarding can reduce clinician adoption friction and accelerate throughput. Finally, leaders should evaluate strategic alliances with software providers, academic institutions, and service partners to broaden solution portfolios and create defensible differentiation. By sequencing these actions-starting with clinical validation, followed by supply resilience investments, and then commercial model diversification-organizations can balance near-term revenue goals with longer-term platform value creation.

A robust mixed-methods research protocol combining stakeholder interviews, clinical observations, regulatory review, and triangulated secondary sources to ensure reliable evidence

The research approach underpinning this analysis employed a mixed-methods design that integrates primary stakeholder engagement with comprehensive secondary synthesis to ensure both rigor and relevance. Primary research included semi-structured interviews with clinicians, procurement specialists, rehabilitation center directors, and device engineers to capture firsthand perspectives on device performance, workflow integration, and purchasing criteria. Supplementing interviews, clinical site visits and observational assessments provided contextual insights into therapy workflows, patient throughput, and training needs. Primary inputs were anonymized and triangulated to protect confidentiality while enabling pattern discovery across settings.

Secondary research encompassed a systematic review of peer-reviewed clinical studies, regulatory filings, product manuals, and technical white papers to validate design claims and identify evidence gaps. Data triangulation methodologies reconciled discrepancies between commercial claims and clinical outcomes, while expert panels were convened to interpret ambiguous findings and prioritize research questions. Quality controls included source provenance checks, methodical inclusion and exclusion criteria for clinical studies, and iterative validation with industry experts to ensure findings were robust and directly applicable to stakeholder decision making. This layered methodology supports actionable insights that are reproducible and relevant to clinical, commercial, and regulatory audiences.

Consolidated conclusions that link technological choices, clinical evidence priorities, and supply resilience to practical strategies for accelerating adoption and value realization

The synthesis of technological trends, segmentation intelligence, tariff implications, and regional dynamics yields a cohesive set of conclusions for executives, clinicians, and investors. First, the market is no longer binary between robotic and non-robotic solutions; rather, a continuum exists in which architecture choices are informed by clinical goals, care setting constraints, and cost considerations. Second, clinical validation and real-world evidence are pivotal to unlocking procurement and reimbursement, making early investment in study design and site partnerships a strategic imperative. Third, supply chain agility-manifested through diversified sourcing, modular designs, and regional assembly-has emerged as a core resilience capability that materially influences product availability and total cost outcomes.

Finally, regional strategies must be tailored: high-acuity centers favor advanced, evidence-rich platforms while ambulatory and homecare markets prioritize usability, affordability, and remote support capabilities. Competitive advantage accrues to organizations that can integrate robust clinical data, scalable service models, and flexible commercial constructs. Taken together, these conclusions point to a clear playbook for stakeholders seeking to accelerate adoption: prioritize evidence generation, design for operational compatibility, and hedge supply-side risks through deliberate sourcing and manufacturing strategies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gait Trainer Market, by Product Type

• 8.1. Fixed
• 8.2. Mobile
• 8.3. Overground
• 8.4. Treadmill Based

9. Gait Trainer Market, by Technology

• 9.1. Non-Robotic
  • 9.1.1. Manual
  • 9.1.2. Mechanical
• 9.2. Robotic
  • 9.2.1. End Effector
  • 9.2.2. Exoskeleton Based

10. Gait Trainer Market, by Assistance Level

• 10.1. Full Body Weight Support
• 10.2. Partial Body Weight Support
• 10.3. Unassisted Training

11. Gait Trainer Market, by Application

• 11.1. Neurological Rehabilitation
  • 11.1.1. Parkinsons
  • 11.1.2. Spinal Cord Injury
  • 11.1.3. Stroke
• 11.2. Orthopedic Rehabilitation
  • 11.2.1. Fracture Recovery
  • 11.2.2. Post-Surgery
• 11.3. Sports Rehabilitation

12. Gait Trainer Market, by End User

• 12.1. Ambulatory Care Facilities
• 12.2. Homecare Settings
• 12.3. Hospitals
• 12.4. Rehabilitation Centers

13. Gait Trainer Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Gait Trainer Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Gait Trainer Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Gait Trainer Market

17. China Gait Trainer Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. AlterG, Inc.
• 18.6. Bionik Laboratories Corp.
• 18.7. Cyberdyne Inc.
• 18.8. Ekso Bionics, Inc.
• 18.9. Hocoma AG
• 18.10. Ottobock SE & Co. KGaA
• 18.11. P&S Mechanics Co., Ltd.
• 18.12. Parker-Hannifin Corporation
• 18.13. ReWalk Robotics Ltd.
• 18.14. Rex Bionics Ltd.
• 18.15. Tyromotion GmbH

LIST OF FIGURES

• FIGURE 1. GLOBAL GAIT TRAINER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL GAIT TRAINER MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL GAIT TRAINER MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL GAIT TRAINER MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL GAIT TRAINER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL GAIT TRAINER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL GAIT TRAINER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL GAIT TRAINER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES GAIT TRAINER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA GAIT TRAINER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL GAIT TRAINER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL GAIT TRAINER MARKET SIZE, BY FIXED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL GAIT TRAINER MARKET SIZE, BY FIXED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL GAIT TRAINER MARKET SIZE, BY FIXED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL GAIT TRAINER MARKET SIZE, BY MOBILE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL GAIT TRAINER MARKET SIZE, BY MOBILE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL GAIT TRAINER MARKET SIZE, BY MOBILE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL GAIT TRAINER MARKET SIZE, BY OVERGROUND, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL GAIT TRAINER MARKET SIZE, BY OVERGROUND, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL GAIT TRAINER MARKET SIZE, BY OVERGROUND, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL GAIT TRAINER MARKET SIZE, BY TREADMILL BASED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL GAIT TRAINER MARKET SIZE, BY TREADMILL BASED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL GAIT TRAINER MARKET SIZE, BY TREADMILL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL GAIT TRAINER MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL GAIT TRAINER MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL GAIT TRAINER MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL GAIT TRAINER MARKET SIZE, BY MECHANICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL GAIT TRAINER MARKET SIZE, BY MECHANICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL GAIT TRAINER MARKET SIZE, BY MECHANICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL GAIT TRAINER MARKET SIZE, BY ROBOTIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL GAIT TRAINER MARKET SIZE, BY ROBOTIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL GAIT TRAINER MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL GAIT TRAINER MARKET SIZE, BY END EFFECTOR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL GAIT TRAINER MARKET SIZE, BY END EFFECTOR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL GAIT TRAINER MARKET SIZE, BY END EFFECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL GAIT TRAINER MARKET SIZE, BY EXOSKELETON BASED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL GAIT TRAINER MARKET SIZE, BY EXOSKELETON BASED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL GAIT TRAINER MARKET SIZE, BY EXOSKELETON BASED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL GAIT TRAINER MARKET SIZE, BY FULL BODY WEIGHT SUPPORT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL GAIT TRAINER MARKET SIZE, BY FULL BODY WEIGHT SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL GAIT TRAINER MARKET SIZE, BY FULL BODY WEIGHT SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL GAIT TRAINER MARKET SIZE, BY PARTIAL BODY WEIGHT SUPPORT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL GAIT TRAINER MARKET SIZE, BY PARTIAL BODY WEIGHT SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL GAIT TRAINER MARKET SIZE, BY PARTIAL BODY WEIGHT SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL GAIT TRAINER MARKET SIZE, BY UNASSISTED TRAINING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL GAIT TRAINER MARKET SIZE, BY UNASSISTED TRAINING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL GAIT TRAINER MARKET SIZE, BY UNASSISTED TRAINING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL GAIT TRAINER MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL GAIT TRAINER MARKET SIZE, BY PARKINSONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL GAIT TRAINER MARKET SIZE, BY PARKINSONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL GAIT TRAINER MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL GAIT TRAINER MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL GAIT TRAINER MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL GAIT TRAINER MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL GAIT TRAINER MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL GAIT TRAINER MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL GAIT TRAINER MARKET SIZE, BY FRACTURE RECOVERY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL GAIT TRAINER MARKET SIZE, BY FRACTURE RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL GAIT TRAINER MARKET SIZE, BY FRACTURE RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL GAIT TRAINER MARKET SIZE, BY POST-SURGERY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL GAIT TRAINER MARKET SIZE, BY POST-SURGERY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL GAIT TRAINER MARKET SIZE, BY POST-SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL GAIT TRAINER MARKET SIZE, BY SPORTS REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL GAIT TRAINER MARKET SIZE, BY SPORTS REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL GAIT TRAINER MARKET SIZE, BY SPORTS REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL GAIT TRAINER MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL GAIT TRAINER MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL GAIT TRAINER MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL GAIT TRAINER MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL GAIT TRAINER MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL GAIT TRAINER MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL GAIT TRAINER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL GAIT TRAINER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL GAIT TRAINER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL GAIT TRAINER MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL GAIT TRAINER MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL GAIT TRAINER MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL GAIT TRAINER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 87. AMERICAS GAIT TRAINER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 88. AMERICAS GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 89. AMERICAS GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 90. AMERICAS GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 91. AMERICAS GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 92. AMERICAS GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 93. AMERICAS GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 94. AMERICAS GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 95. AMERICAS GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 96. AMERICAS GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 97. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 98. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 99. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 100. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 101. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 102. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 103. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 104. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 105. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 106. NORTH AMERICA GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 107. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 108. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 109. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 110. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 111. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 112. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 113. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 114. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 115. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 116. LATIN AMERICA GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 118. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 119. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 120. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 121. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 122. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 127. EUROPE GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 128. EUROPE GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 129. EUROPE GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 130. EUROPE GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 131. EUROPE GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 132. EUROPE GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 133. EUROPE GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 134. EUROPE GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 135. EUROPE GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 136. EUROPE GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 137. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 138. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 139. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 140. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 141. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 142. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 143. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 144. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 145. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 146. MIDDLE EAST GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 147. AFRICA GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 148. AFRICA GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 149. AFRICA GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 150. AFRICA GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 151. AFRICA GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 152. AFRICA GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 153. AFRICA GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 154. AFRICA GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 155. AFRICA GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 156. AFRICA GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 157. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 158. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 159. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 160. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 161. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 162. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 163. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 164. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 165. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 166. ASIA-PACIFIC GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 167. GLOBAL GAIT TRAINER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 168. ASEAN GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 169. ASEAN GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 170. ASEAN GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 171. ASEAN GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 172. ASEAN GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 173. ASEAN GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 174. ASEAN GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 175. ASEAN GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 176. ASEAN GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 177. ASEAN GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 178. GCC GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 179. GCC GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 180. GCC GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 181. GCC GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 182. GCC GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 183. GCC GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 184. GCC GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 185. GCC GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 186. GCC GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 187. GCC GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 188. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 189. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 190. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 191. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 192. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 193. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 194. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 195. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 196. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 197. EUROPEAN UNION GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 198. BRICS GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 199. BRICS GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 200. BRICS GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 201. BRICS GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 202. BRICS GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 203. BRICS GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 204. BRICS GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 205. BRICS GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 206. BRICS GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 207. BRICS GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 208. G7 GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 209. G7 GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 210. G7 GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 211. G7 GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 212. G7 GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 213. G7 GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 214. G7 GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 215. G7 GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 216. G7 GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 217. G7 GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 218. NATO GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 219. NATO GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 220. NATO GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 221. NATO GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 222. NATO GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 223. NATO GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 224. NATO GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 225. NATO GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 226. NATO GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 227. NATO GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 228. GLOBAL GAIT TRAINER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 229. UNITED STATES GAIT TRAINER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 230. UNITED STATES GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 231. UNITED STATES GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 232. UNITED STATES GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 233. UNITED STATES GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 234. UNITED STATES GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 235. UNITED STATES GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 236. UNITED STATES GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 237. UNITED STATES GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 238. UNITED STATES GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 239. CHINA GAIT TRAINER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 240. CHINA GAIT TRAINER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 241. CHINA GAIT TRAINER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 242. CHINA GAIT TRAINER MARKET SIZE, BY NON-ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 243. CHINA GAIT TRAINER MARKET SIZE, BY ROBOTIC, 2018-2032 (USD MILLION)
• TABLE 244. CHINA GAIT TRAINER MARKET SIZE, BY ASSISTANCE LEVEL, 2018-2032 (USD MILLION)
• TABLE 245. CHINA GAIT TRAINER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 246. CHINA GAIT TRAINER MARKET SIZE, BY NEUROLOGICAL REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 247. CHINA GAIT TRAINER MARKET SIZE, BY ORTHOPEDIC REHABILITATION, 2018-2032 (USD MILLION)
• TABLE 248. CHINA GAIT TRAINER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)